Literature DB >> 9665302

Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria.

C Edlund1, S Sabouri, C E Nord.   

Abstract

The in vitro activity of BAY 12-8039 against 360 anaerobic clinical isolates was determined by the agar dilution method and compared to that of five other antimicrobial agents. BAY 12-8039 and imipenem were the most active agents tested. The following MIC90 values were determined for BAY 12-8039: Peptostreptococcus spp. (50 isolates), 1 mg/l; Propionibacterium acnes (30 isolates). 0.25 mg/l; Clostridium perfringens (30 isolates), 0.5 mg/l; Clostridium difficile (50 isolates), 2 mg/l; Bacteroides fragilis (50 isolates), 1 mg/l; non-fragilis Bacteroides, Porphyromonas, and Prevotella spp. (100 isolates), 2 mg/l; and Fusobacterium spp. (50 isolates), 0.25 mg/l. The results of the present study show that BAY 12-8039 may be useful in the treatment and prophylaxis of anaerobic infections.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9665302     DOI: 10.1007/bf01691117

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  6 in total

1.  In vitro activity of Bay 12-8039, a new 8-methoxyquinolone.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Anaerobic infections in humans: an overview.

Authors:  S M Finegold
Journal:  Anaerobe       Date:  1995-02       Impact factor: 3.331

3.  Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes.

Authors:  K E Aldridge; D S Ashcraft
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

4.  In vitro activity of BAY 12-8039, a new fluoroquinolone.

Authors:  J M Woodcock; J M Andrews; F J Boswell; N P Brenwald; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

5.  In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.

Authors:  A Dalhoff; U Petersen; R Endermann
Journal:  Chemotherapy       Date:  1996 Nov-Dec       Impact factor: 2.544

6.  In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria.

Authors:  C E Nord
Journal:  Clin Infect Dis       Date:  1996-12       Impact factor: 9.079

  6 in total
  13 in total

Review 1.  Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.

Authors:  C E Nord
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

2.  Susceptibilities of Propionibacterium acnes ophthalmic isolates to moxifloxacin.

Authors:  P Dali; E R Giugliano; E M Vellozzi; M A Smith
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 3.  Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.

Authors:  Dhara Shah; Minh-Duc Dang; Rodrigo Hasbun; Hoonmo L Koo; Zhi-Dong Jiang; Herbert L DuPont; Kevin W Garey
Journal:  Expert Rev Anti Infect Ther       Date:  2010-05       Impact factor: 5.091

Review 4.  Future novel therapeutic agents for Clostridium difficile infection.

Authors:  Hoonmo L Koo; Kevin W Garey; Herbert L Dupont
Journal:  Expert Opin Investig Drugs       Date:  2010-07       Impact factor: 6.206

5.  In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.

Authors:  Ellie J C Goldstein; Diane M Citron; Yumi A Warren; Kerin L Tyrrell; C Vreni Merriam; Helen Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 6.  The potential for emerging therapeutic options for Clostridium difficile infection.

Authors:  Harsh Mathur; Mary C Rea; Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Gut Microbes       Date:  2014

Review 7.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile.

Authors:  Larbi Dridi; Jacques Tankovic; Béatrice Burghoffer; Frédéric Barbut; Jean-Claude Petit
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

Review 9.  Moxifloxacin.

Authors:  J A Balfour; L R Wiseman
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

10.  Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA.

Authors:  G Ackermann; Y J Tang; R Kueper; P Heisig; A C Rodloff; J Silva; S H Cohen
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.